50 Gibson Drive, Kings Hill
ME19 4AF West Malling, Kent
Phone: +44 1732 22-0022
Fax: +44 1732 22-0024
Department/ Name Address
Julie Ross Tel: 44-1732-22-0022
Slaes and Marketing email@example.com
Number of employees 100-499
Year of foundation 1981
Area of business Diagnostics
Genzyme offers a unique portfolio for diagnostic manufactures and clinical laboratories worldwide. Our Diagnostics Division has three key product areas these are Intermediates, Clinical Chemistry, and Point of Care.
A prime manufacturer of a large number of critical intermediates such as enzymes, antibodies and substrates that are supplied in bulk to diagnostic kit manufacturers. With competencies in R&D, commercial fermentation, purification and lyophilisation, Genzyme is a key partner for custom manufacture.
Our Clinical Chemistry product line is manufactured in cGMP and ISO 9001 certified facilities, offering an array of critical raw materials and finished reagents covering three main disease states – cardiovascular, diabetes and pancreatitis.
Point of care diagnostic testing allows physicians to diagnose patients more rapidly than traditional laboratory based testing. Rapid results can enable better patient management decisions, improved outcomes, and a reduction in the overall cost of care. Areas covered include enteric disease, infectious disease and pregnancy.
Genzyme Diagnostics is a business unit of Genzyme Corporation, which since it was created in 1981, has focused on creating innovative therapies for unmet medical needs, utilizing a variety of technology platforms. In addition Genzyme Corporation has built multiple, sustainable growing businesses and has established a global infrastructure, while remaining financially strong. Medical areas in which it has specialised are lysosomal storage disorders, orthopaedics, renal disease, immune-mediated disease, cardiovascular disease, cancer and immunotherapy
Genzyme with headquarters in Cambridge Massachusetts, is a global corporation with almost 6000 employees in 28 countries. Its products are marketed in more than 80 countries and total revenues in 2002 were $1.33 billion; in the first quarter of 2003 revenues were $380 million.
Visit our website at www.genzymediagnostics.com